Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow. Here, we report the effects of the novel histone deacetylase inhibitor panobinostat (LBH589) in combination with doxorubicin on AML cells. Panobinostat exhibited potent anti-AML activity in all AML cell lines tested and in primary AML cells from patients (IC 50 o20 nM). In addition, panobinostat potentiated the action of several standard-of-care anti-AML compounds, particularly, doxorubicin. The molecular effects induced by panobinostat and doxorubicin treatment were investigated by analyzing gene expression, cell cycle, apoptosis and signaling pathways. Analyses of gene expression profiles identified 588 genes whose expression was exclusively affected by the combination of panobinostat and doxorubicin. The combination induced AML cell death by an increase in the mitochondrial outer membrane permeability and release of cytochrome c from the mitochondria, resulting in caspasedependent apoptosis and accompanied by the upregulation of Bax, Bak and, particularly, Bad. The drug combination provoked a strong activation of a DNA damage response, indicating that this combination may trigger cell death by a mechanism that induced DNA double-strand breaks. These data indicate that the combination of panobinostat and doxorubicin may be an effective therapy for the treatment of AML.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous, clonal disorder of hematopoietic progenitor cells that lose the ability to normally differentiate and to respond to regulators of proliferation. 1 Although important advances have been made in the knowledge of the pathophysiologic bases of this disease, the treatment of AML has remained largely unchanged for more than 30 years. 2, 3 Thus the identification of novel drugs for the treatment of AML is a significant unmet need, as 20-40% of patients do not respond to initial chemotherapy, and approximately 50% of responding patients will eventually relapse. 1, 2 Epigenetic deregulation is a key feature in the pathophysiology of AML, resulting in aberrant transcription of genes involved in cell growth, proliferation, differentiation and apoptosis. 4 Histone acetylation is a major epigenetic mechanism for the regulation of gene expression and is maintained by the activities of histone deacetylases (HDACs) and histone acetyltransferases (HATs). Rather, in normal cells, there is a balance between the activities of HDACs and HATs. 5, 6 In leukemic cells, this balance is disrupted by mechanisms that include chromosomal translocations, which promote oncogenesis by recruitment of HDAC activities, as well as aberrant expression of HDAC or HAT enzymes. 7, 8 These events lead to altered levels and patterns of histone acetylation and deacetylation that alter normal gene expression. 7, 8 A prominent example of an HDACassociated translocation in leukemogenesis is the t(8;21) that results in the fusion protein AML1-ETO. AML1-ETO combines the DNA-binding activities of a critical regulator of hematopoiesis with the HDAC-recruiting capabilities of a co-repressor to generate dominant-negative inhibitors of AML1-responsive promoters, resulting in the silencing of genes involved in myeloid differentiation. 7 Given the epigenetic deregulation observed in AML pathogenesis, agents such as histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors are in clinical development for AML treatment. HDACi have not only been classically proposed to restore the balance of histone acetylation and regulation of gene expression but also to target many other nonhistone HDAC substrates involved in the regulation of multiple cellular functions, including cell cycle, cell proliferation and cell death. In transformed cells, HDACi have been shown to induce growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive-oxygenspecies-induced cell death, mitotic cell death and senescence. 9, 10 HDACi have shown particular efficacy in hematologic malignancies, and the hydroxamic acid (vorinostat, SAHA) is the first to be approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. Vorinostat and other HDACi have been already tested in phase I/II trials in patients with refractory acute leukemias. 11 Attempts to improve HDACi potency led to the development of a novel class of cinnamic acid hydroxamate compounds, being panobinostat (LBH589), a prominent example of this group of agents. Panobinostat has shown strong preclinical activity in several preclinical cancer models, [12] [13] [14] and is currently in clinical trials for a number of hematologic malignancies, including lymphomas, leukemias and myelodysplastic syndromes.
In the present study, we have investigated the in vitro anti-AML activities of panobinostat alone and in combination with other agents. Our results demonstrate that panobinostat has potent activity against AML cell lines and primary AML cells from patients. Owing to the large body of evidence indicating that combination treatments often result in an increased efficacy in AML, we investigated potential synergy of panobinostat with well-established anti-AML agents that are currently in the clinic. A significant level of synergy in combination with doxorubicin was observed. Moreover, the combination of panobinostat and doxorubicin was found to affect the expression of a significant number of genes, which were unaffected by either of the two compounds as single agents. These data have been the bases for a clinical trial that will test this combination in refractory AML patients.
Materials and methods

Reagents and immunochemicals
Cell culture media, serum and penicillin-streptomycin were from Invitrogen Corporation (Gaithersburg, MD, USA). Panobinostat was provided by Novartis Pharmaceuticals (East Hannover, NJ, USA). Doxorubicin, daunorubicin, cytarabine (Ara-C) and fludarabine were purchased from Sigma Chemical (Madrid, Spain). Bortezomib was obtained from Millennium Pharmaceuticals (Cambridge, MA, USA). Annexin V-FITC was obtained from BD Biosciences (San Diego, CA, USA). Z-VAD-FMK, Z-IETD-FMK, Z-LEHD-FMK, SB203580 and SP600125 were from Calbiochem (San Diego, CA, USA). Other generic chemicals were purchased from Sigma Chemical, Roche Biochemicals (Mannheim, Germany) or Merck (Darmstadt, Germany).
The origins of the different monoclonal antibodies used in the western blotting analyses were as follows: anti-Bcl-2, anti-Mcl-1 and anti-Bak were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-p-Histone H4, anti-p-H2AX, anti-p53, anti-Bcl-X, anti-Bad, anti-Bax, anti-PARP, anti-caspase-3, anti-caspase-7, anti-caspase-8, anti-caspase-9, anti-p-p38, anti-p38, anti-pATM, anti-pCHK1, anti-pCHK2, anti-RAD51 and anti-RAD54B were from Cell Signaling (Boston, MA, USA); the anti-cytochrome c was from BD Biosciences. The horseradish-peroxidaseconjugated secondary antibodies were from Amersham (Buckinghamshire, UK).
Cell culture
All AML cell lines (HEL, HL60, KG-1 and MV4-11) were cultured at 37 1C in a humidified atmosphere with 5% CO 2 -95% air. HL60 was derived from a French-AmericanBritish (FAB) M2 AML patient; HEL derived from an FAB M6 AML patient and carried an activating mutation of JAK2; MV4-11 was derived from an FAB M4 AML patient and carried an mixed-lineage leukemia rearrangement and an FLT3-internal tandem duplication (ITD); KG-1 was derived from a patient diagnosed of a blastic crisis of an MPD and carried a rearrangement of FGFR1. Cell lines and cells obtained from AML patients were cultured in RPMI 1640 medium with L-glutamine and supplemented with antibiotics (penicillin at 100 U/ml, streptomycin at 100 mg/ml) and 10% fetal bovine serum (FBS) for cell lines or 20% FBS for patient cells. The source of the AML cell lines was described previously. 15 Cell proliferation, cell cycle and apoptosis assays
The proliferation of AML cells was examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays, as described. 13 For cytometric evaluation of apoptosis in AML cell lines, we washed 1 Â 10 6 HEL cells with phosphate-buffered saline (PBS) and resuspended in binding buffer (10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl 2 ). Cells were incubated with 5 ml of Annexin V-FITC for 10 min in the dark at room temperature, followed by addition of 10 ml propidium iodide (PI; Calbiochem).
To qualitatively evaluate the mitochondrial transmembrane potential (DC m ), we incubated cells in PBS with 20 nM 3,3 0 -dihexyloxacarbocyanine iodide (DiOC 6 (3); Molecular Probes, Leiden, the Netherlands) for 20 min at 37 1C and washed with PBS, followed by addition of 10 ml PI (Calbiochem) and fluorescence-activated cell sorting analysis. 13 Evaluation of the potential synergism of panobinostat with other compounds HEL cells were treated for 24 and 48 h with increasing doses of panobinostat and doxorubicin as indicated. Cell viability was analyzed by MTT assay. The potency of the combination was quantified with the Calcusyn software (Biosoft, Ferguson, MO, USA), which is based on the Chou-Talalay method 16 that calculates a combination index (CI) with the following interpretation: CI41, antagonistic effect; CI ¼ 1, additivity; CIo1, synergistic effect.
Ex vivo experiments in freshly isolated AML cells
The cytometric analyses of apoptosis have been described elsewhere. 15 Briefly, bone marrow (BM) cells were obtained from six AML patients at diagnosis before any treatment, 1 Â 10 6 BM cells were incubated in six-well plates with panobinostat (10 nM), doxorubicin (500 nM), both, or without any drug (control) for 18 h at 37 1C in a humidified atmosphere with 5% CO 2 -95% air. The drug concentrations were selected based on the median plasma levels achieved in patients for these drugs and our own results of cell lines. Using quadruple staining (Annexin V-FITC/CD33-PE/CD45-PerCP/CD34-APC), we were able to identify and distinguish the blast cell population (CD34À/ þ , CD33À/ þ , CD45dim) from the normal residual lymphocytes (CD45 þ , SSClo) and quantify the number of apoptotic cells in each cell population. The percentage of apoptotic events was adjusted according to the proportion of apoptotic cells in the control group. Statistical significance between the combination and each drug in monotherapy was analyzed by using the Mann-Whitney U-test.
Microarray RNA analyses HEL cells were treated with panobinostat (10 nM) or doxorubicin (500 nM) for 24 h and with the combination for 12 h. Total RNA was extracted using Trizol reagent from Life Technologies, (Rockville, MD, USA) and purified with RNAeasy Mini kit from Qiagen (Valencia, CA, USA). RNA integrity was verified with the Agilent 2100 Bioanalyzer from Agilent (Santa Clara, CA, USA). Double-stranded cDNA and biotinylated cRNA were synthesized with T7-polyT primer and the BioArray RNA labeling kit from Enzo (New York, NY, USA), respectively. Labeled RNA was fragmented and hybridized to Affymetrix HG-U133 Plus 2.0 GeneChip oligonucleotide arrays from Affymetrix (Santa Clara, CA, USA), which were scanned in a GeneArray scanner and analyzed using the DNA-Chip Analyzer software from DChip (Boston, MA, USA). Changes in expression greater than twofold were considered significant.
Western blotting
Cells were collected and centrifuged at 10 000 g for 2 min. Cells were washed with PBS and lysed in ice-cold lysis buffer (140 mM NaCl, 10 mM EDTA, 10% glycerol, 1% Nonidet P-40, 20 mM Tris (pH 7.0), 1 mM pepstatin, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM sodium orthovanadate). Western blotting analyses were performed as described previously. 13 
Subcellular fractionation
HEL cells were harvested in isotonic mitochondrial buffer 13 (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM pepstatin, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM sodium orthovanadate) and Dounce homogenized by 60-70 strokes. Samples were transferred to Eppendorf tubes and centrifuged at 770 g for 10 min at 4 1C to separate nuclei and unbroken cells. The resulting supernatant was centrifuged at 10 000 g for 25 min at 4 1C to obtain the mitochondrial pellet. The supernatant was further centrifuged at 100 000 g for 1 h at 4 1C to yield the final soluble cytosolic fraction.
Results
Panobinostat induces histone acetylation in AML cells
To verify whether panobinostat induces hyperacetylation of histones in AML, we treated HEL cells with different concentrations for 24 h and with panobinostat (100 nM) for different times, and acetylation of histone H4 was analyzed by western blotting. HEL cells exhibited a progressive increase in histone H4 acetylation correlating with panobinostat dose ( Figure 1a ) and length of treatment ( Figure 1b ).
Action of panobinostat in AML cells
We assessed the biologic effect of panobinostat on AML cells by using MTT assays on four different representative AML cell lines: HEL, HL60, KG1 and MV4-11. Treatment with increasing doses of panobinostat (1-1000 nM) for 48 h suppressed MTT metabolization, indicating potent inhibition of cell proliferation and viability ( Figure 1c ). IC 50 values for panobinostat in these cell lines were 9 nM (HEL), 7 nM (HL60), 17 nM (KG1) and 6 nM (MV4-11). Comparison of these IC 50 values for panobinostat with those of other compounds commonly used in AML treatment indicated that panobinostat was more potent than Ara-C, fludarabine, doxorubicin and bortezomib (IC 50 ¼ 740, 362, 220 and 14 nM, respectively, for HEL cells; data not shown).
Synergy of panobinostat with doxorubicin in AML
To investigate whether panobinostat could potentiate the activity of other anti-AML agents, we treated HEL cells with combinations of panobinostat and four other compounds; Ara-C, fludarabine, doxorubicin and bortezomib ( Figure 2a ). As shown in Figure 2a , the combination of panobinostat with Ara-C, fludarabine or bortezomib was found to further decrease AML cell viability, compared with single-agent treatment. However, especially significant effects were observed in combination with doxorubicin. This potentiation was also explored using daunorubicin, another anthracycline which is commonly used in the treatment of AML, displaying similar results as those shown with doxorubicin (Supplementary data). To verify whether panobinostat was able to increase the effect of doxorubicin in other AML cell lines (including cell lines partially resistant to doxorubicin), we tested the effect of the combination on the viability of HEL, HL60, KG1 and MV4-11 cell lines for treatment periods of 24 and 48 h. As shown in Figure 2b , the combination of panobinostat and doxorubicin resulted in significant growth inhibition of all cell lines tested, compared to that seen with single-agent treatment. The CI values for the combination consistently indicated significant synergy, as defined by CIo1, ranging from 0.05 to 0.53 in HEL; 0.11 to 0.26 in HL60; 0.04 to 0.09 in KG1 and 0.21 to 1.66 in MV4-11 after 24 h (Table 1 ). In the MV4-11 cell line, the CI range value decreased up to 0.17-0.41 after 48 h of treatment (data not shown). The effects of sequential drug treatment were also explored, showing similar results when panobinostat and doxorubicin were administered sequentially, rather than simultaneously (data not shown).
The effects of panobinostat with doxorubicin on primary leukemic cells were assessed on cells from six AML patients. As Synergy of panobinostat and doxorubicin in AML P Maiso et al illustrated in Figure 2c , the combination of 10 nM panobinostat and 500 nM doxorubicin significantly increased the number of apoptotic blasts, as measured by Annexin V staining, indicating increased antileukemic activity compared to the single-agent compounds. Interestingly, all samples were sensitive to the combination, despite the heterogeneity of their biologic features: patient 1 had a relapsed FAB M5 AML; patients 2, 3 and 5 were newly diagnosed patients with FAB M1 AML whereas patient 6 was an M2 AML; patient 4 was a blast crisis of a chronic myelomonocytic leukemia. Cytogenetic and fluorescence in situ hybridization studies were performed in four of the samples without any abnormality in any of the patients. Regarding mutational status, it was performed in three patients: 5 displayed both abnormalities and patient 6 was FLT3-ITD negative with mutated NPM-1. Notably, there was no increase in the levels of apoptosis in normal residual lymphocytes, suggesting cancer-cell-specific cytotoxicity of the combination.
A conjunct analysis of the activity of panobinostat and doxorubicin in the blast population of the six patients shows statistically significant superiority for the combination as compared to the drugs in monotherapy (Figure 2d ). 
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Doxorubicin potentiates the HDACi activity of panobinostat
On the basis of highly synergistic activity of panobinostat with doxorubicin, we decided to explore the anti-AML mechanism of the drug combination. The effects of the compounds were analyzed, both as single agents and in combination, on gene expression profiles (GEP), cell cycle, apoptosis and signaling pathways in AML cells. First, we evaluated whether doxorubicin could affect histone acetylation. As shown in Figure 3a , doxorubicin failed to provoke any increase in histone H4 acetylation. In contrast, co-incubation of doxorubicin and panobinostat resulted in a strong potentiation of histone H4 acetylation (Figure 3b ).
Panobinostat plus doxorubicin combination provokes unique gene expression modifications
As the drug combination also strongly synergized on histone H4 acetylation and these biochemical modifications are expected to affect a wide array of genes, we decided to perform gene expression profiling to gain further insights into the synergistic effect of panobinostat plus doxorubicin on AML cells.
Changes in the GEP of HEL cells were analyzed before and after treatment with panobinostat (10 nM), doxorubicin (500 nM) and the combination. Array analysis using RNA from three independent experiments was performed using the Affymetrix HG-U133 Plus 2.0 GeneChip, containing 54 613 probe sets. GEP analysis of treated HEL cells identified 285 genes with significantly altered expression (transcriptional changes in gene expression of X2-fold) after 24 h of treatment with panobinostat and 43 genes after 24 h of treatment with doxorubicin. However 12 h of treatment with the combination of panobinostat and doxorubicin was sufficient to induce the deregulation of 841 genes (Figure 3c) . Of the 841 genes identified, 588 genes were found to be exclusively affected by the combination. The majority of alterations in gene expression in response to all treatments were found to be due to gene upregulation (data not shown). The above results indicate that the GEP of cells treated with the combination is not simply the sum of genes altered by single-agent treatment.
Analysis of the 588 genes exclusively altered by the drug combination identified cell cycle and apoptosis as the two most significantly affected functional categories (Table 2) . Treatment with panobinostat plus doxorubicin resulted in decreased expression of genes involved in cell cycle, such as Cyclin B1 (FC: À3.04), and increased the expression of Cyclin G2 (FC: 5.49). The combination treatment also resulted in decreased expression of several genes involved in apoptosis: AVEN (FC: À2.58), which acts as an inhibitor of the apoptosome by inhibiting caspase-9 activation, 17 Bcl-X (FC: À2.96), TNFRSF25 (FC: À3.48) or HSPA5 (FC: À3.87), and increased expression of genes, such as BTG1 (FC: 5.47), KLRC1 (FC: 2.34) or BNIP3L (FC: 2.17) ( Table 2 ). Moreover, c-jun was upregulated after treatment with panobinostat (FC: 3.77) and, particularly, with doxorubicin (FC: 26.30), but the expression was significantly increased upon treatment with the combination (FC: 58.38).
Panobinostat and doxorubicin synergistically induce caspase-dependent cell death
The effect of the panobinostat and doxorubicin combination on apoptotic cell death was next investigated. The combination of panobinostat and doxorubicin induced a significant increase in Annexin-V-positive cells, as compared to either of the two compounds alone (Figure 4a ). Treatment with panobinostat plus doxorubicin induced cleavage of poly-(ADP-ribose)polymerase (PARP), caspase-3, -7, -8 and -9, with the generation of active, low molecular weight cleaved fragments within the first 12 h of treatment (Figure 4b ). No effect was observed at 24 h with either of the two drugs used alone.
To investigate the role of caspase activation in the antileukemic action of panobinostat plus doxorubicin, we assessed the ability of the caspase-3, -8 and -9 inhibitors, ZVAD-FMK, Z-IETD-FMK and Z-LEHD-FMK to inhibit the cytotoxicity of panobinostat plus doxorubicin. HEL cells were preincubated for 60 min with Z-VAD-FMK, Z-IETD-FMK or Z-LEHD-FMK, followed by the addition of panobinostat and doxorubicin for 24 h. As shown in Figure 4c , preincubation with caspase inhibitors resulted in decreased Annexin V staining, suggesting inhibition of compound-induced cell death. Together, these results indicate that the combination of panobinostat and doxorubicin activates the caspase-dependent apoptotic pathway to induce cell death in AML cells.
To further explore the mechanisms of apoptotic cell death induced by panobinostat and doxorubicin, we assessed the effects of treatment on the mitochondrial membrane potential (DC m ), which reflects the permeability of the mitochondrial outer membrane. Mitochondria are critically involved in the triggering of apoptotic cell death and the loss of mitochondrial membrane potential has been suggested to be one of the earliest events in apoptosis. 18 Analysis of DC m by the use of the mitochondrial membrane potential probe DioC 6 (3) indicated a decrease in DC m in cells treated with panobinostat plus doxorubicin, and this effect was greater than with either of the two compounds used alone (Figure 4d ).
Bcl-2 family members act as important regulators of mitochondrial outer membrane permeability. Western blot Regarding the proapoptotic Bcl-2 family members, only a modest increase in some of them such as Bad or Bak was observed with the combination (Figure 4e ). The increase in mitochondrial outer membrane permeability favors the release of cytochrome c that together with caspase-9 and Apaf-1 constitutes the apoptosome, a macromolecular structure that causes activation of the effector, caspase-3. 18 Subcellular fractionation of HEL cells treated for 24 h with panobinostat, doxorubicin or both revealed that the combination caused a treatment-dependent translocation of cytochrome c from the mitochondrial to the cytosolic fraction (Figure 4e ). Neither panobinostat nor doxorubicin single agents were found to induce release of cytochrome c.
Panobinostat and doxorubicin provoke a DNA damage response
To assess if the increase in apoptosis also reflected DNA damage, we evaluated the phosphorylation of H2AX, a surrogate marker of DNA DSB. Treatment of HEL cells with panobinostat plus doxorubicin induced a marked H2AX phosphorylation after 24 h of incubation (Figure 5a ), whereas this increase was not detected in cells treated with panobinostat or doxorubicin as single agents. This suggests that the induction of DNA damage may be a consequence of the mechanism of action of the combination. Western blotting studies of other proteins related with DNA damage pathway indicated that the double combination of panobinostat and doxorubicin upregulated the levels of pATM after 6 h of treatment and downregulated the levels of pCHK1, pCHK2 and RAD54B, all substrates of ATM. Western blot analyses also demonstrated that the combination of panobinostat and doxorubicin induced the inactivation/cleavage of RAD51. RAD51 participates in the DNA response pathway and it is associated with the activation of double-strand break (DSBs) repair. 19 These studies confirmed that panobinostat plus doxorubicin provoked a DNA damage response (DDR) probably after inducing DSBs in the DNA.
Discussion
Over the past 30 years, there has been minimal progress in the treatment of AML, and a substantial proportion of patients either fail to respond to induction treatment or eventually relapse. AML has become recognized as a paradigm of epigenetic deregulation in cancer. Compounds such as HDACi, which target epigenetic processes, may thus represent a novel therapeutic approach to AML, and several agents have shown preliminary efficacy in AML. Table 2 Genes exclusively deregulated by the combination of panobinostat and doxorubicin in AML cells HEL cells were treated with panobinostat (10 nM), doxorubicin (500 nM) or the combination of both. RNA was isolated, and GEP analysis was performed as described in Materials and methods.
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In the present study, we have evaluated the effects of HDAC inhibition by panobinostat used both as single agent and in combination with several standard-of-care agents. Panobinostat and TSA, 27, 28 which have demonstrated activity in AML cells at micromolar concentrations. The observed anticancer activity of panobinostat in AML is consistent with the activity observed in other tumor models. 12, 13, 29 In addition to potency, the compound demonstrates significant synergistic inhibition of cell viability in combination with Ara-C, and particularly with doxorubicin, in all AML cell lines tested, as well as in primary leukemic cells from patients. These results suggest that the inhibition of HDAC activity, combined with doxorubicin, may be highly effective in inducing anticancer effects in AML patients.
The analysis of the mechanism of action of panobinostat plus doxorubicin indicates that this combination affects several pathways involved in the control of cell-cycle progression, apoptosis and DDR. Notably, the combination was found to deregulate a substantial number of genes that were not affected by the compounds as single agents. Therefore, the action of the combined treatment cannot be explained as a mere addition of the effects of the single-drug treatments. Thus, new signaling routes may be affected by the drug combination.
Panobinostat plus doxorubicin was found to induce AML cell death through caspase-dependent apoptosis. Bcl-2 family members have been shown to regulate mitochondrial outer membrane permeability, 18, 30 and the loss of the mitochondrial membrane potential has also been shown to reflect an increase in the permeability of the outer mitochondrial membrane allowing the release of proapoptotic proteins such as cytochrome c. Panobinostat plus doxorubicin caused the release of cytochrome c from mitochondria into the cytosol, caspase-9 and -3 cleavage, and PARP cleavage. The importance of the activation of caspases in panobinostat plus doxorubicin-induced cell death was demonstrated using caspase inhibitors, of which the pan-caspase inhibitor, Z-VAD-FMK, was the most efficient in preventing the treatment-dependent induction of apoptosis. These data identify caspase-dependent apoptosis in the mechanism of action of the cytotoxic effects of panobinostat plus doxorubicin in AML. Although the release of cytochrome c and caspase cleavage are involved in the mechanism of action of other HDAC inhibitors and doxorubicin, this effect was clearly more potent in AML cells treated with the combination of panobinostat and doxorubicin.
In addition to the observed effects, the combination of panobinostat and doxorubicin also triggers DDR, as indicated by its action on pH2AX and the deregulation of several proteins implicated in the ATM and DNA repair pathways. These studies confirmed that panobinostat plus doxorubicin provoked a DDR response probably after inducing DSBs in the DNA.
The lower doses and shorter duration of treatment required for the antileukemic effects of the combination, together with the observed cancer-cell-specific activity, may translate into decreased toxicity for normal cells, indicating a potential favorable therapeutic window. The doses used in the in vitro experiments correspond to clinically achievable concentrations observed in phase I trials. Moreover, the absence of differences in efficacy observed with simultaneous compared to sequential treatment would probably favor a schedule using first anthracycline at conventional dose (with or without cytarabine) followed by low doses of panobinostat (starting from 20 mg up to 40 mg, 3 days per week), to maintain the efficacy of both drugs and try to diminish the potential toxicity.
In summary, we have identified a synergistic cytotoxicity and a mechanism of action for the combination of panobinostat and doxorubicin in AML. Our preclinical studies suggest that the efficacy of the combination of panobinostat and doxorubicin in the treatment of AML merits investigation in the clinic. As a matter of fact, these preclinical data have seeded the design of a clinical trial in AML that is being developed in our University Hospital.
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